Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | US

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Newron Pharmaceuticals S.p.A. Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.	Italy	NWRN
NEXGEL, INC. Develops and manufactures advanced hydrogels for healthcare, OTC, and consumer applications.	United States of America	NXGL
NextCell Pharma AB Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.	Sweden	NXTCL
NextCure, Inc. Clinical-stage biopharma developing novel immunomedicines for cancer and other diseases.	United States of America	NXTC
NGeneBio Co., Ltd. Provides NGS-based diagnostics, software, and liquid biopsy for precision oncology and healthcare.	South Korea	354200
NIBEC CO., LTD. Biotech CDMO creating regenerative products with peptide and biomaterial technologies.	South Korea	138610
NIPPON CHEMIPHAR CO., LTD. Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.	Japan	4539
Nippon Shinyaku Co.,Ltd. Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.	Japan	4516
Nkarta, Inc. Developing off-the-shelf NK cell therapies for cancer and autoimmune diseases.	United States of America	NKTX
NKMAX Co., Ltd. Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.	South Korea	182400